These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 32876349)

  • 21. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
    Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
    J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
    Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
    Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
    Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T
    Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939
    [No Abstract]   [Full Text] [Related]  

  • 24. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease.
    Kotze PG; Ma C; Almutairdi A; Al-Darmaki A; Devlin SM; Kaplan GG; Seow CH; Novak KL; Lu C; Ferraz JGP; Stewart MJ; Buresi M; Jijon H; Mathivanan M; Heatherington J; Martin ML; Panaccione R
    Aliment Pharmacol Ther; 2018 Sep; 48(6):626-637. PubMed ID: 30063077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease.
    Parikh A; Fox I; Leach T; Xu J; Scholz C; Patella M; Feagan BG
    Inflamm Bowel Dis; 2013 Jul; 19(8):1691-9. PubMed ID: 23591599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
    Amiot A; Serrero M; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Vuitton L; Viennot S; Bouguen G; Abitbol V; Fumery M; Gagniere C; Bouhnik Y;
    Aliment Pharmacol Ther; 2019 Jul; 50(1):40-53. PubMed ID: 31165509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
    BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
    Schreiber S; Dignass A; Peyrin-Biroulet L; Hather G; Demuth D; Mosli M; Curtis R; Khalid JM; Loftus EV
    J Gastroenterol; 2018 Sep; 53(9):1048-1064. PubMed ID: 29869016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
    J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
    Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
    Cohen RD; Bhayat F; Blake A; Travis S
    J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.
    Colombel JF; Sandborn WJ; Reinisch W; Peyrin-Biroulet L; Panaccione R; Rutgeerts P; Hanauer SB; Ghosh S; Van Assche G; Robinson AM; Lau W; Maa JF; Huang B; Pappalardo B; Read H
    Aliment Pharmacol Ther; 2018 Jan; 47(2):219-228. PubMed ID: 29159817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
    Smith MA; Mohammad RA
    Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis.
    Hahn L; Beggs A; Wahaib K; Kodali L; Kirkwood V
    Am J Health Syst Pharm; 2015 Aug; 72(15):1271-8. PubMed ID: 26195652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
    Pugliese D; Privitera G; Crispino F; Mezzina N; Castiglione F; Fiorino G; Laterza L; Viola A; Bertani L; Caprioli F; Cappello M; Barberio B; Ricci C; Balestrieri P; Daperno M; Pluchino D; Rizzello F; Scribano ML; Sablich R; Pastorelli L; Manguso F; Variola A; Di Sario A; Grossi L; Armuzzi A;
    Aliment Pharmacol Ther; 2022 Jul; 56(1):95-109. PubMed ID: 35876062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice].
    Shapina MV; Nanaeva BA
    Ter Arkh; 2020 Apr; 92(2):67-73. PubMed ID: 32598721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis.
    Pellet G; Stefanescu C; Carbonnel F; Peyrin-Biroulet L; Roblin X; Allimant C; Nachury M; Nancey S; Filippi J; Altwegg R; Brixi H; Fotsing G; de Rosamel L; Shili S; Laharie D;
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):494-501. PubMed ID: 30213584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.
    Danese S; Subramaniam K; Van Zyl J; Adsul S; Lindner D; Roth J; Vermeire S
    Aliment Pharmacol Ther; 2021 Jan; 53(2):265-272. PubMed ID: 33210333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials.
    Feagan BG; Bhayat F; Khalid M; Blake A; Travis SPL
    J Crohns Colitis; 2018 Jul; 12(8):905-919. PubMed ID: 29788248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.